BioCentury | Jul 25, 2019
Product Development

The universe of universal flu vaccines

With at least 10 flu vaccines in the clinic that could confer protection against a wide range of strains, dispensing with the yearly seasonal vaccine may be in reach. Currently, seasonal flu vaccines consist of...
BioCentury | Aug 1, 2016
Financial News

BARDA awards Altimmune anthrax contract

...is an intranasal recombinant protein antigen ( rPA )-based vaccine. Altimmune formerly was known as Vaxin...
BioCentury | Aug 3, 2015
Clinical News

HepTcell: Phase I started

...dose-escalation, U.K. Phase I trial to evaluate HepTcell in 72 patients with chronic HBV infection. Vaxin Inc....
BioCentury | Jul 23, 2015
Tools & Techniques

Gene therapy's coming of age

...Therapeutics Inc. , Shenzhen SiBiono GeneTech Co. Ltd. , Taxus Cardium Pharmaceuticals Group Inc. and Vaxin Inc....
BioCentury | Apr 14, 2015
Company News

Management tracks

...compliance at Amylin Pharmaceuticals Inc. , which Bristol-Myers Squibb Co. (NYSE:BMY) acquired. Infectious disease company Vaxin Inc....
BioCentury | Mar 2, 2015
Company News

Immune Targeting Systems, Vaxin deal

...Vaxin is acquiring fellow vaccine company Immune for an undisclosed sum. Vaxin will gain an HBV...
...Vaxin expects the deal to close this month. Immune Targeting Systems Ltd. , London, U.K. Vaxin Inc....
BioCentury | Feb 23, 2015
Financial News

Vaxin completes venture financing

Vaxin Inc. , Rockville, Md. Business: Infectious Date completed: 2015-02-17 Type: Venture financing Raised: $16 million Investors: Novartis Venture Funds; HealthCap; Truffle Capital; Redmont Venture Partners WIR Staff Infectious...
BioCentury | Nov 13, 2014
Cover Story

Boosting adjuvants

For all the talk of new vaccines, not much attention has been paid to the need for better adjuvants, which have remained stuck on alum-based products for decades. The NIH is committing up to $70...
BioCentury | Oct 6, 2014
Company News

Vaxine, GlaxoSmithKline, NIH infectious news

NIH's National Institute of Allergy and Infectious Diseases (NIAID) awarded five-year contracts to Vaxine, GlaxoSmithKline's Corixa Corp. unit and five research institutions developing new vaccine adjuvants that boost responses by activating the adaptive immune system....
BioCentury | Oct 1, 2014
Politics & Policy

NIAID funds development of new vaccine adjuvants

NIH's National Institute of Allergy and Infectious Diseases awarded five-year contracts to seven research institutions developing new vaccine adjuvants that boost responses by activating the adaptive immune system. The agency said total funding for all...
Items per page:
1 - 10 of 37
BioCentury | Jul 25, 2019
Product Development

The universe of universal flu vaccines

With at least 10 flu vaccines in the clinic that could confer protection against a wide range of strains, dispensing with the yearly seasonal vaccine may be in reach. Currently, seasonal flu vaccines consist of...
BioCentury | Aug 1, 2016
Financial News

BARDA awards Altimmune anthrax contract

...is an intranasal recombinant protein antigen ( rPA )-based vaccine. Altimmune formerly was known as Vaxin...
BioCentury | Aug 3, 2015
Clinical News

HepTcell: Phase I started

...dose-escalation, U.K. Phase I trial to evaluate HepTcell in 72 patients with chronic HBV infection. Vaxin Inc....
BioCentury | Jul 23, 2015
Tools & Techniques

Gene therapy's coming of age

...Therapeutics Inc. , Shenzhen SiBiono GeneTech Co. Ltd. , Taxus Cardium Pharmaceuticals Group Inc. and Vaxin Inc....
BioCentury | Apr 14, 2015
Company News

Management tracks

...compliance at Amylin Pharmaceuticals Inc. , which Bristol-Myers Squibb Co. (NYSE:BMY) acquired. Infectious disease company Vaxin Inc....
BioCentury | Mar 2, 2015
Company News

Immune Targeting Systems, Vaxin deal

...Vaxin is acquiring fellow vaccine company Immune for an undisclosed sum. Vaxin will gain an HBV...
...Vaxin expects the deal to close this month. Immune Targeting Systems Ltd. , London, U.K. Vaxin Inc....
BioCentury | Feb 23, 2015
Financial News

Vaxin completes venture financing

Vaxin Inc. , Rockville, Md. Business: Infectious Date completed: 2015-02-17 Type: Venture financing Raised: $16 million Investors: Novartis Venture Funds; HealthCap; Truffle Capital; Redmont Venture Partners WIR Staff Infectious...
BioCentury | Nov 13, 2014
Cover Story

Boosting adjuvants

For all the talk of new vaccines, not much attention has been paid to the need for better adjuvants, which have remained stuck on alum-based products for decades. The NIH is committing up to $70...
BioCentury | Oct 6, 2014
Company News

Vaxine, GlaxoSmithKline, NIH infectious news

NIH's National Institute of Allergy and Infectious Diseases (NIAID) awarded five-year contracts to Vaxine, GlaxoSmithKline's Corixa Corp. unit and five research institutions developing new vaccine adjuvants that boost responses by activating the adaptive immune system....
BioCentury | Oct 1, 2014
Politics & Policy

NIAID funds development of new vaccine adjuvants

NIH's National Institute of Allergy and Infectious Diseases awarded five-year contracts to seven research institutions developing new vaccine adjuvants that boost responses by activating the adaptive immune system. The agency said total funding for all...
Items per page:
1 - 10 of 37